Menu Search
Equities

Cyfuse Biomedical KK

4892:TYO

Cyfuse Biomedical KK

Actions
  • Price (JPY)463.00
  • Today's Change-21.00 / -4.34%
  • Shares traded51.60k
  • 1 Year change-43.19%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Cyfuse Biomedical KK's revenues fell -83.68% from 374.48m to 61.11m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 473.96m to a larger loss of 589.21m.
Gross margin55.40%
Net profit margin-1,245.95%
Operating margin-1,463.01%
Return on assets-18.36%
Return on equity-24.09%
Return on investment-21.62%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Cyfuse Biomedical KK fell by 563.53m. Cash Flow from Financing totalled 18.24m or 29.84% of revenues. In addition the company used 562.30m for operations while cash used for investing totalled 19.47m.
Cash flow per share-85.34
Price/Cash flow per share--
Book value per share335.21
Tangible book value per share334.66
More ▼

Balance sheet in JPYView more

Cyfuse Biomedical KK appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.98% of the market capitalization can be attributed to its 3.87bn and debt could be paid in full if management chose.
Current ratio5.61
Quick ratio5.52
Total debt/total equity0.2933
Total debt/total capital0.2268
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.